ALLUVI: A DETAILED ANALYSIS INTO THE MEDICATION'S PROMISE

Alluvi, initially dubbed LY3414901, represents a noteworthy advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable effectiveness in early trial data, with impressive we